8-K
filed February 7, 2023, 6:59 PM ET
ticker VRTX
CIK 0000875320
earnings
confidence high
sentiment positive
materiality 0.85
Vertex reports FY22 product revenue $8.93B (+18% YoY); guides FY23 $9.55-$9.7B
VERTEX PHARMACEUTICALS INC / MA
2022-FY EPS reported
$12.82
revenue$8,930,700,000
- Full year 2022 product revenue $8.93B, up 18% vs 2021; GAAP net income $3.32B, up 42%.
- Q4 product revenue $2.30B (+11% YoY); GAAP diluted EPS $3.15, non-GAAP $3.76.
- FY2023 product revenue guidance of $9.55B-$9.7B, implying 7-9% growth.
- Exa-cel regulatory submissions validated in EU and UK; US rolling BLA underway.
- CF drug TRIKAFTA/KAFTRIO generated $7.69B in FY22, up 35% from $5.70B in FY21.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
VERTEX PHARMACEUTICALS INC / MA reported Three Months Ended December 31, 2022 results: revenue $ 2,303, net income $ 819, EPS $ 3.15. Guidance initiated.
- Period
- Three Months Ended December 31, 2022
- Revenue
- $ 2,303
- Net income
- $ 819
- EPS
- $ 3.15
- Guidance
- initiated
- Result
- reported results
Exact text from the filing
Product revenues, net $ 2,303 $ 2,073 11% $ 8,931 $ 7,573 18% TRIKAFTA/KAFTRIO $ 2,022 $ 1,693 $ 7,687 $ 5,697 SYMDEKO/SYMKEVI $ 34 $ 80 $ 180 $ 420 ORKAMBI $ 111 $ 147 $ 511 $ 772 KALYDECO $ 136 $ 152 $ 553 $ 684 GAAP operating income $ 1,034 $ 878 18% $ 4,307 $ 2,782 55% Non-GAAP operating income* $ 1,150 $ 997 15% $ 4,793 $ 3,232 48% GAAP net income $ 819 $ 770 6% $ 3,322 $ 2,342 42% Non-GAAP net income* $ 978 $ 777 26% $ 3,855 $ 2,513 53% GAAP net income per share - diluted $ 3.15 $ 3.00 5% $ 12.82 $ 9.01 42%
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
VERTEX PHARMACEUTICALS INC / MA reported Twelve Months Ended December 31, 2022 results: revenue $ 8,931, net income $ 3,322, EPS $ 12.82. Guidance initiated.
- Period
- Twelve Months Ended December 31, 2022
- Revenue
- $ 8,931
- Net income
- $ 3,322
- EPS
- $ 12.82
- Guidance
- initiated
- Result
- reported results
Exact text from the filing
Product revenues, net $ 2,303 $ 2,073 11% $ 8,931 $ 7,573 18% TRIKAFTA/KAFTRIO $ 2,022 $ 1,693 $ 7,687 $ 5,697 SYMDEKO/SYMKEVI $ 34 $ 80 $ 180 $ 420 ORKAMBI $ 111 $ 147 $ 511 $ 772 KALYDECO $ 136 $ 152 $ 553 $ 684 GAAP operating income $ 1,034 $ 878 18% $ 4,307 $ 2,782 55% Non-GAAP operating income* $ 1,150 $ 997 15% $ 4,793 $ 3,232 48% GAAP net income $ 819 $ 770 6% $ 3,322 $ 2,342 42% Non-GAAP net income* $ 978 $ 777 26% $ 3,855 $ 2,513 53% GAAP net income per share - diluted $ 3.15 $ 3.00 5% $ 12.82 $ 9.01 42%
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.